Use of benzimidazole derivatives as antibacterial agents

Abstract: The compound represented by the formula; [wherein R¹ stands for hydrogen, methoxy or trifluoromethyl; R² and R³, being the same as, or different from each other, stand for hydrogen or methyl; R⁴ stands for optionally substituted hydrocarbon residue; and n denotes 0 or 1] or a salt thereof show excellent antibacterial activities, against the genus Campylobacter, especially against Campylobacter pylori, and they are used for preventing or treating infectious diseases caused by the said bacteria.

Description: Description for the following Contracting States : AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE FIELD OF THE INVENTION This invention relates to the use of pyridine derivatives, known as a compounds having anti-ulcer activity, for the manufacture of a medicament for preventing or treating infectious diseases caused by Campylobacter pylori. BACKGROUND OF THE INVENTION Bacteria belonging to the genus Campylobacter have been known as possible causes of gastro-intestinal disorders of animals. For example, Campylobacter pylori is isolated with high frequency from the gastic mucosa of patients suffering from gastritis and peptic ulcer, and, several investigators have suggested that this organism might participate in the pathogenesis of these diseases. (cf: The Journal of Infectious Disease, Vol. 153, pp. 664-669, 1986 and The Lancet, May 27, pp. 1167-1168, 1989). Furthermore, the close association between the presence of Campylobacter pylori and duodenal ulcers has been also suggested. (cf: Digestion, Vol. 37, pp. 16-30, 1987). Until now some studies dealing with the effectiveness of antibiotics, bismuth citrate, anti-ulcer cents (cimetidine, ranitidine, etc.) or related compounds in the treatment of the infectious diseases associated with the genus Campylobacter have been reported (cf: Journal of Antimicrobial Chemotherapy, Vol. 17, pp. 309-314, 1986), but no practical use for them has been realized yet. As mentioned above, no clinically effective pharmaceutical agents against bacterial infections due to the genus Campylobacter have been brought into existence. The present inventors have studied the genus Campylobacter, and the present invention has been accomplished. SUMMARY OF THE INVENTION The present invention relates to the use of a compound of the formula (I); wherein R¹ stands for hydrogen, methoxy or trifluoromethyl; R² and R³, being the same or different from each other, stand for hydrogen or methyl; and R⁴ stands for a straight or branched chain C₁₋₆ alkyl, C₂₋₆ alkenyl or C₂₋₆ alkynyl group which may optionally be substituted and n denotes 0 or 1; with the proviso that if R², R³ and R⁴ are methyl and n denotes 1, R¹ is not 5-methoxy; or a pharmacologically acceptable salt thereof, for the manufacture of a medicament for preventing or treating infectious diseases caused by the microorganism belonging to Campylobacter pylori. DETAILED DESCRIPTION OF THE INVENTION The medicaments produced according to the present invention show excellent antibacterial activities, against the genus Campylobacter, especially against Campylobacter pylori, and they are used for preventing or treating infectious diseases caused by the said bacteria. In the compound (I), preferable examples of the hydrocarbon residue in the optionally substituted hydrocarbon shown by R⁴ include 1-6 C straight or branched chain alkyl groups, 2-6 C alkenyl groups and alkynyl groups; the alkyl groups are exemplified by methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, t-butyl, pentyl, 2-methylbutyl, hexyl, 4-methylpentyl, etc.; the alkenyl groups are exemplified by vinyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 3-methyl-2-pentenyl, 4-methyl-3-pentenyl, etc.; the alkynyl groups are exemplified by ethynyl, 2-propynyl, 1-methyl-2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-butynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-methyl-3-pentynyl, 2-hexynyl, etc. As the substituents, mention is made of fluorine and 1-3C alkoxy groups. The number of substituents ranges from 1 to 9, in the case of fluorine, and the number is 1 or 2, in the case of alkoxy groups. Examples of thus substituted compounds include 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, 2,2,3,3-tetrafluoropropyl, 1,1,1,3,3,3-hexafluoro-2-propyl, 2,2,3,3,4,4,4-heptafluorobutyl, 2,2,3,3,4,4-hexafluorobutyl, 2,2,3,3,4,4,5,5-octafluoropentyl, 2,2,3,3,4,4,5,5,5-nonafluoropentyl, cis-2-fluoro-2-butenyl, 2,2,3,4,4-pentafluoro-3-butenyl, 1,1,1-trifluoro-3-pentyn-2-yl, methoxymethyl, ethoxymethyl, propoxyethyl, 2-methoxypropyl, 3-methoxypropyl, 3-ethoxypropyl, 4-methoxybutyl, trans-3-methoxy-2-propenyl, trans-3-methoxy-2-butenyl, 4-methoxy-2-butynyl, etc. Among these, fluorinated 2-6C straight or branched chain alkyl groups are especially preferable. The compound (I) can be produced by a known method, for example, the method disclosed in EP-A-174726, and methods disclosed in the laid-open official gazette of EP-A-268956 and in the laid-open official gaztte of GB-A-2134523, or methods analogous thereto. Salts of the compound (I) are exemplified by pharmaceutically acceptable ones obtained by a known method (laid-open official gazette of European Patent No. 124495) or methods analogous thereto, such as salts of alkali metal or alkaline earth metal, e.g. sodium, potassium, calcium, magnesium, etc. The compound (I) shows antibacterial action against the genus Campylobacter, for example, Campylobacter pylori. In the following, the antibacterial action of the compound (I) is described by way of Experimental Examples. Experimental Example 1 The minimum inhibitory concentration (MIC) of each compound was determined by the agar-plate dilution method based on the standard method advocated by Japan Society of Chemotherapy [cf: Chemotherapy, Jan. '81, p.76]. The volume of agar medium per plate was 20 mℓ. The compounds tested are shown in Table 1. Compound No. (I) R¹ R² R³ R⁴ n 1 H CH₃ H CH₂CF₃ 1 3 H CH₃ H CH₂CF₂CF₃ 1 4 H CH₃ H CH₂CF₂CF₂H 1 5 H CH₃ H CH₂(CF₂)₂CF₂H 1 6 H CH₃ H CH₂CF₃ 0 7 H H H iso-butyl 0 8 5-CF₃ H H iso-butyl 0 9 5-CF₃ H H iso-propyl 0 10 5-CF₃ H H CH₂CH=CH₂ 0 11 5-CF₃ H H CH₂C≡CH 0 12 H CH₃ H CH₂CF₂CF₂H 0 13 H CH₃ H CH₂CF₂CF₃ 0 14 H CH₃ H CH₂(CF₂)₂CF₂H 0 Each of the test compounds was dissolved in dimethylsulfoxide at a concentration of 80 mg/mℓ or 40 mg/mℓ, and diluted 10 times with sterile distilled water. Furthermore, the aqueous solution of 8 mg/mℓ or 4 mg/mℓ was diluted serially 2-fold with sterile distilled water. To 2 mℓ of the diluted solution was added 18 mℓ of Brucella agar (BBL Microbiology Systems, Becton Dickinson and Co. Cockeysruilie, MD21030) containing 7% defibrinated horse blood (manufactured by Nippon Bio-supp. Center) and mixed well. Test strains frozen at -80°C in Brucella broth (BBL) containing 10% horse serum were thawed and inoculated on a Brucella agar slant medium containing 7% defibrinated horse blood. The medium was incubated anaerobically at 37°C for 3 days in a jar containing a piece of sponge sufficiently impregnated with water and Campy Pak™ (BBL). The organisms grown on the slant medium were collected and suspended in a Brucella broth to correspond to the turbidity of about 10⁸ CFU/mℓ of common bacteria. One platinum loop of inoculum was streaked on the medium plates for determination. The plates were incubated under the same conditions as described above. After a three-day incubation, the growth of bacteria was observed with the naked eye, and MIC (unit:µg/mℓ) was determined. The results are shown in Table 2 and Table 3. Compound Test strains A B C D E F G 1 12.5 6.25 6.25 6.25 6.25 6.25 3.13 3 3.13 6.25 3.13 3.13 3.13 1.56 6.25 4 1.56 6.25 6.25 1.56 1.56 0.78 6.25 5 1.56 3.13 1.56 1.56 1.56 1.56 6.25 As is clear from Table 2 and Table 3, compounds 1 and 3 to 14 respectively showed antibacterial activities against the genus Campylobacter. And, the derivatives in which R⁴ of the Compound (I) is a fluorinated alkyl group (compounds 1, 3, 4, 5, 6, 12, 13 and 14) showed stronger antibacterial activity when compared with other derivatives. Experimental Example 2 Antibacterial activities of some compounds of the present invention against aerobic common bacteria were examined. MICs (unit:µg/mℓ) of the test compounds, i.e. compounds 1 and 6 employed in Experimental Example 1, were determined by the standard agar-plate dilution method of Japan Society of Chemotherapy. The results are shown in Table 4. As shown in Table 4, compounds 1 and 6 did not possess any antibacterial action against the aerobic bacteria. This suggests that the Compound (I) has a selective antibacterial activity against the genus Campylobacter. Subsequently, the toxicity of the Compound (I) was investigated. Oral administration of compounds 1 and 6 to mice (200 mg/kg) resulted in no dead animals, thus the Compound (I) is low in toxicity. As described above, the Compound (I) has a strong antibacterial activity against the genus Campylobacter, e.g. Campylobacter pylori; and is of low toxicity. Thus, it can be used for the therapy of infectious diseases due to bacteria belonging to the genus Campylobacter (e.g. diarrhea, food poisoning, etc.) in mammals (e.g. mouse, rat, rabbit, dog, men, etc.). In this case, since the Compound (I) is selectively active against the genus Compylobacter, its administration does not induce the changes in the intestinal flora observed frequently in common antibiotic therapy (e.g. penicillin, cephalosporin, quinolon, etc.). Thus, treatment with the Compound (I) is not accompanied with the severe risk of undesirable side-effects due to replacement of bacteria (e.g. enteritis, pseudomembranous colitis, etc.). Furthermore, since the Compound (I) shows a very unique antibacterial spectrum, its mode of action is considered to be different from that of any of the known antibiotics. Thus, the administration of the Compound (I) is unlikely to induce the acquisition of drug resistance of other species of bacteria or the cross-tolerance with other antibiotics. When the Compound (I) is used as an antibiotic agent for preventing or treating said infectious diseases, it can be administered orally in a dosage form of capsules, tablets, granules, etc. by formulating with pharmacologically acceptable carriers, such as excipients (e.g. lactose, starch, sucrose, etc.), disintegrators (e.g. starch, carboxymethyl-cellulose calcium, etc.), lubricants (e.g. magnesium stearate, talc, etc.), binders (e.g. hydroxypropyl-cellulose, hydroxypropylmethyl-cellulose, macrogol, etc.), and so on, and it also can be administered parenterally in a dosage form of injectable solutions which desirably have a concentration of the Compound (I) of 0.1 to 20 mg/mℓ, particularly 2 to 10 mg/mℓ. Working Example In the following, the present invention is illustrated in a more concrete manner. Example 1 Nonpareils, 1650 g, [sugar core prepared by coating sucrose (75 weight parts) with corn starch (25 weight parts) according to a per se known method, 20∼28 mesh] were brought into the CF granulator (CF-360, Freund Industrial Co., Ltd., Japan), and coated, while being sprayed with 1050 mℓ of a hydroxypropylcellulose solution [2% (w/v)] at 30 mℓ/min., first with the spraying powder 1 and then with the spraying powder 2, both of which had been prepared by mixing the ingredients listed below, at the rate of 60 g/min. at room temperature with a rotor rotating at 200 rpm, dried in vacuo at 40°C for 16 hours, and sieved through round sieves, to give spherical granules (14∼32 mesh) having a core. [spraying powder 1] compound (1) 450 g magnesium carbonate 336 g granulated sugar 297 g corn starch 300 g L-HPC 354 g [degree of substitution with hydroxypropyl group: 10.0∼13.0% (w/w), mean particle size : not more than 30 µm] [spraying powder 2] granulated sugar 300 g corn starch 246 g L-HPC (the same one as above) 246 g 3,8000 g of the granules obtained as above were brought into a fluidized-bed coating vessel Ohkawara Co., Japan), subjected to enteric coating by spraying the enteric coating film solution described below at the rate of 50 mℓ/min. under the controlled conditions of inlet air at 65°C and material temperature at 40°C, to give enteric coated spherical granules having a core. The said granules were mixed with talc and light anhydrous silicic acid, then the mixture was filled into No. 1 hard capsules with a capsule filling machine (Parke-Davis & Co., USA) to give capsules. [Enteric coating film solution] Eudragit L30D-55 2,018 g (solid:605g) talc 182 g polyethylene glycol 6000 60 g titanium oxide 60 g Tween 80 27 g water 4,230 mℓ The dosage of the capsules is, for an adult man, one capsule after each meal per day. Example 2 A 1000 mg quantity of compound (1) was dispersed in distilled water for injection, and 3 ml of 1N-aqueous sodium hydroxide solution was added to dissolve the compound (1), followed by addition of water to make up to a total of 50 ml and sterile filtration by the conventional method. The resulting filtrate was filled in 1 ml portions into vials of a 12 cm³ capacity, followed by lyophilization by means of a conventional technique. The lyophilized powder as contained in vials was dissolved in Solvent A (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid and 2 ml of propylene glycol being admixed with ethanol to make up to a total of 4 ml), Solvent B (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid, 1.2 ml of polyethylene glycol 400 and 1.2 ml of ethanol being admixed with distilled water for injection to make up to a total of 4 ml), Solvent C (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid, 1.2 ml of ethanol and 1.2 ml of propylene glycol being admixed with distilled water for injection to make up to a total of 4 ml) and Solvent D (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid and 2.5 ml of polyethylene glycol 400 bing admixed with distilled water for injection to make up to the total of 4 ml), respectively, to perform inspection for their solubilities as well as to conduct investigation into appearance and contents immediately after dissolution and after storage at 25°C for 24 hours. The results are shown in Table 5. The lyophilized power showed excellent solubilities in all of these solvents, and was able to be dissolved quickly. In addition to this, the resulting solutions were observed to produce slight changes in appearance immediately after dissolution and after storage for 24 hours, but the changes were found to be so slight that they in no way influence the injectable solution. The solutions were found to show no change in the stage of solution while being observed to decrease slightly in content of compound (1). These solutions can be used as injectable solutions. Description for the following Contracting State : GR FIELD OF THE INVENTION This invention relates to the use of pyridine derivatives, known as a compounds having anti-ulcer activity, for the manufacture of a medicament for preventing or treating infectious diseases caused by Campylobacter pylori. BACKGROUND OF THE INVENTION Bacteria belonging to the genus Campylobacter have been known as possible causes of gastro-intestinal disorders of animals. For example, Campylobacter pylori is isolated with high frequency from the gastic mucosa of patients suffering from gastritis and peptic ulcer, and, several investigators have suggested that this organism might participate in the pathogenesis of these diseases. (cf: The Journal of Infectious Disease, Vol. 153, pp. 664-669, 1986 and The Lancet, May 27, pp. 1167-1168, 1989). Furthermore, the close association between the presence of Campylobacter pylori and duodenal ulcers has been also suggested. (cf: Digestion, Vol. 37, pp. 16-30, 1987). Until now some studies dealing with the effectiveness of antibiotics, bismuth citrate, anti-ulcer agents (cimetidine, ranitidine, etc.) or related compounds in the treatment of the infectious diseases associated with the genus Campylobacter have been reported (cf: Journal of Antimicrobial Chemotherapy, Vol. 17, pp. 309-314, 1986), but no practical use for them has been realized yet. As mentioned above, no clinically effective pharmaceutical agents against bacterial infections due to the genus Campylobacter have been brought into existence. The present inventors have studied the genus Campylobacter, and the present invention has been accomplished. SUMMARY OF THE INVENTION The present invention relates to the use of a compound of the formula (I); wherein R¹ stands for hydrogen, methoxy or trifluoromethyl; R² and R³, being the same or different from each other, stand for hydrogen or methyl; and R⁴ stands for a straight or branched chain C₁₋₆ alkyl, C₂₋₆ alkenyl or C₂₋₆ alkynyl group which may optionally be substituted and n denotes 0 or 1; with the proviso that if R², R³ and R⁴ are methyl and n denotes 1, R¹ is not 5-methoxy; or a pharmacologically acceptable salt thereof, for the manufacture of a medicament for preventing or treating infectious diseases caused by the microorganism belonging to Campylobacter pylori. DETAILED DESCRIPTION OF THE INVENTION The medicaments produced according to the present invention show excellent antibacterial activities, against the genus Campylobacter, especially against Campylobacter pylori, and they are used for preventing or treating infectious diseases caused by the said bacteria. In the compound (I), preferable examples of the hydrocarbon residue in the optionally substituted hydrocarbon shown by R⁴ include 1-6 C straight or branched chain alkyl groups, 2-6 C alkenyl groups and alkynyl groups; the alkyl groups are exemplified by methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, t-butyl, pentyl, 2-methylbutyl, hexyl, 4-methylpentyl, etc.; the alkenyl groups are exemplified by vinyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 3-methyl-2-pentenyl, 4-methyl-3-pentenyl, etc.; the alkynyl groups are exemplified by ethynyl, 2-propynyl, 1-methyl-2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-butynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-methyl-3-pentynyl, 2-hexynyl, etc. As the substituents, mention is made of fluorine and 1-3C alkoxy groups. The number of substituents ranges from 1 to 9, in the case of fluorine, and the number is 1 or 2, in the case of alkoxy groups. Examples of thus substituted compounds include 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, 2,2,3,3-tetrafluoropropyl, 1,1,1,3,3,3-hexafluoro-2-propyl, 2,2,3,3,4,4,4-heptafluorobutyl, 2,2,3,3,4,4-hexafluorobutyl, 2,2,3,3,4,4,5,5-octafluoropentyl, 2,2,3,3,4,4,5,5,5-nonafluoropentyl, cis-2-fluoro-2-butenyl, 2,2,3,4,4-pentafluoro-3-butenyl, 1,1,1-trifluoro-3-pentyn-2-yl, methoxymethyl, ethoxymethyl, propoxyethyl, 2-methoxypropyl, 3-methoxypropyl, 3-ethoxypropyl, 4-methoxybutyl, trans-3-methoxy-2-propenyl, trans-3-methoxy-2-butenyl, 4-methoxy-2-butynyl, etc. Among these, fluorinated 2-6C straight or branched chain alkyl groups are especially preferable. The compound (I) can be produced by a known method, for example, the method disclosed in EP-A-174726, and methods disclosed in the laid-open official gazette of EP-A-268956 and in the laid-open official gaztte of GB-A-2134523, or methods analogous thereto. Salts of the compound (I) are exemplified by pharmaceutically acceptable ones obtained by a known method (laid-open official gazette of European Patent No. 124495) or methods analogous thereto, such as salts of alkali metal or alkaline earth metal, e.g. sodium, potassium, calcium, magnesium, etc. The compound (I) shows antibacterial action against the genus Campylobacter, for example, Campylobacter pylori. In the following, the antibacterial action of the compound (I) is described by way of Experimental Examples. Experimental Example 1 The minimum inhibitory concentration (MIC) of each compound was determined by the agar-plate dilution method based on the standard method advocated by Japan Society of Chemotherapy [cf: Chemotherapy, Jan. '81, p.76]. The volume of agar medium per plate was 20 mℓ. The compounds tested are shown in Table 1. Compound No. (I) R¹ R² R³ R⁴ n 1 H CH₃ H CH₂CF₃ 1 2 5-OCH₃ CH₃ CH₃ CH₃ 1 3 H CH₃ H CH₂CF₂CF₃ 1 4 H CH₃ H CH₂CF₂CF₂H 1 5 H CH₃ H CH₂(CF₂)₂CF₂H 1 6 H CH₃ H CH₂CF₃ 0 7 H H H iso-butyl 0 8 5-CF₃ H H iso-butyl 0 9 5-CF₃ H H iso-propyl 0 10 5-CF₃ H H CH₂CH=CH₂ 0 11 5-CF₃ H H CH₂C≡CH 0 12 H CH₃ H CH₂CF₂CF₂H 0 13 H CH₃ H CH₂CF₂CF₃ 0 14 H CH₃ H CH₂(CF₂)₂CF₂H 0 Each of the test compounds was dissolved in dimethylsulfoxide at a concentration of 80 mg/mℓ or 40 mg/mℓ, and diluted 10 times with sterile distilled water. Furthermore, the aqueous solution of 8 mg/mℓ or 4 mg/mℓ was diluted serially 2-fold with sterile distilled water. To 2 mℓ of the diluted solution was added 18 mℓ of Brucella agar (BBL Microbiology Systems, Becton Dickinson and Co. Cockeysruilie, MD21030) containing 7% defibrinated horse blood (manufactured by Nippon Bio-supp. Center) and mixed well. Test strains frozen at -80°C in Brucella broth (BBL) containing 10% horse serum were thawed and inoculated on a Brucella agar slant medium containing 7% defibrinated horse blood. The medium was incubated anaerobically at 37°C for 3 days in a jar containing a piece of sponge sufficiently impregnated with water and Campy Pak™ (BBL). The organisms grown on the slant medium were collected and suspended in a Brucella broth to correspond to the turbidity of about 10⁸ CFU/mℓ of common bacteria. One platinum loop of inoculum was streaked on the medium plates for determination. The plates were incubated under the same conditions as described above. After a three-day incubation, the growth of bacteria was observed with the naked eye, and MIC (unit:µg/mℓ) was determined. The results are shown in Table 2 and Table 3. Compound Test strains A B C D E F G 1 12.5 6.25 6.25 6.25 6.25 6.25 3.13 2 25 25 12.5 12.5 25 25 12.5 3 3.13 6.25 3.13 3.13 3.13 1.56 6.25 4 1.56 6.25 6.25 1.56 1.56 0.78 6.25 5 1.56 3.13 1.56 1.56 1.56 1.56 6.25 As is clear from Table 2 and Table 3, compounds 1 to 14 respectively showed antibacterial activities against the genus Campylobacter. And, the derivatives in which R⁴ of the Compound (I) is a fluorinated alky group (compounds 1, 3, 4, 5, 6, 12, 13 and 14) showed stronger antibacterial activity when compared with other derivatives. Experimental Example 2 Antibacterial activities of some compounds of the present invention against aerobic common bacteria were examined. MICs (unit:µg/mℓ) of the test compounds, i.e. compounds 1, 2 and 6 employed in Experimental Example 1, were determined by the standard agar-plate dilution method of Japan society of Chemotherapy. The results are shown in Table 4. As shown in Table 4, compounds 1, 2 and 6 did not possess any antibacterial action against the aerobic bacteria. This suggests that the Compound (I) has a selective antibacterial activity against the genus Campylobacter. Subsequently, the toxicity of the Compound (I) was investigated. Oral administration of compounds 1 and 6 to mice (200 mg/kg) resulted in no dead animals, thus the Compound (I) is low in toxicity. As described above, the Compound (I) has a strong antibacterial activity against the genus Campylobacter, e.g. Campylobacter pylori; and is of low toxicity. Thus, it can be used for the therapy of infectious diseases due to bacteria belonging to the genus Campylobacter (e.g. diarrhea, food poisoning, etc.) in mammals (e.g. mouse, rat, rabbit, dog, men, etc.). In this case, since the Compound (I) is selectively active against the genus Compylobacter, its administration does not induce the changes in the intestinal flora observed frequently in common antibiotic therapy (e.g. penicillin, cephalosporin, quinolon, etc.). Thus, treatment with the Compound (I) is not accompanied with the severe risk of undesirable side-effects due to replacement of bacteria (e.g. enteritis, pseudomembranous colitis, etc.). Furthermore, since the Compound (I) shows a very unique antibacterial spectrum, its mode of action is considered to be different from that of any of the known antibiotics. Thus, the administration of the Compound (I) is unlikely to induce the acquisition of drug resistance of other species of bacteria or the cross-tolerance with other antibiotics. When the Compound (I) is used as an antibiotic agent for preventing or treating said infectious diseases, it can be administered orally in a dosage form of capsules, tablets, granules, etc. by formulating with pharmacologically acceptable carriers, such as excipients (e.g. lactose, starch, sucrose, etc.), disintegrators (e.g. starch, carboxymethyl-cellulose calcium, etc.), lubricants (e.g. magnesium stearate, talc, etc.), binders (e.g. hydroxypropyl-cellulose, hydroxypropylmethyl-cellulose, macrogol, etc.), and so on, and it also can be administered parenterally in a dosage form of injectable solutions which desirably have a concentration of the Compound (I) of 0.1 to 20 mg/mℓ, particularly 2 to 10 mg/mℓ. Working Example In the following, the present invention is illustrated in a more concrete manner. Example 1 Nonpareils, 1650 g, [sugar core prepared by coating sucrose (75 weight parts) with corn starch (25 weight parts) according to a per se known method, 20∼28 mesh] were brought into the CF granulator (CF-360, Freund Industrial Co., Ltd., Japan), and coated, while being sprayed with 1050 mℓ of a hydroxypropylcellulose solution [2% (w/v)] at 30 mℓ/min., first with the spraying powder 1 and then with the spraying powder 2, both of which had been prepared by mixing the ingredients listed below, at the rate of 60 g/min. at room temperature with a rotor rotating at 200 rpm, dried in vacuo at 40°C for 16 hours, and sieved through round sieves, to give spherical granules (14∼32 mesh) having a core. [spraying powder 1] compound (1) 450 g magnesium carbonate 336 g granulated sugar 297 g corn starch 300 g L-HPC 354 g [degree of substitution with hydroxypropyl group: 10.0∼13.0% (w/w), mean particle size : not more than 30 µm] [spraying powder 2] granulated sugar 300 g corn starch 246 g L-HPC (the same one as above) 246 g 3,8000 g of the granules obtained as above were brought into a fluidized-bed coating vessel (Ohkawara Co., Japan), subjected to enteric coating by spraying the enteric coating film solution described below at the rate of 50 mℓ/min. under the controlled conditions of inlet air at 65°C and material temperature at 40°C, to give enteric coated spherical granules having a core. The said granules were mixed with talc and light anhydrous silicic acid, then the mixture was filled into No. 1 hard capsules with a capsule filling machine (Parke-Davis & Co., USA) to give capsules. [Enteric coating film solution] Eudragit L30D-55 2,018 g (solid:605g) talc 182 g polyethylene glycol 6000 60 g titanium oxide 60 g Tween 80 27 g water 4,230 mℓ The dosage of the capsules is, for an adult man, one capsule after each meal per day. Example 2 A 1000 mg quantity of compound (1) was dispersed in distilled water for injection, and 3 ml of 1N-aqueous sodium hydroxide solution was added to dissolve the compound (1), followed by addition of water to make up to a total of 50 ml and sterile filtration by the conventional method. The resulting filtrate was filled in 1 ml portions into vials of a 12 cm³ capacity, followed by lyophilization by means of a conventional technique. The lyophilized powder as contained in vials was dissolved in Solvent A (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid and 2 ml of propylene glycol being admixed with ethanol to make up to a total of 4 ml), Solvent B (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid, 1.2 ml of polyethylene glycol 400 and 1.2 ml of ethanol being admixed with distilled water for injection to make up to a total of 4 ml), Solvent C (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid, 1.2 ml of ethanol and 1.2 ml of propylene glycol being admixed with distilled water for injection to make up to a total of 4 ml) and Solvent D (which was composed of 50 mg of N-methylglucamine, 0.27 ml of 1N-hydrochloric acid and 2.5 ml of polyethylene glycol 400 bing admixed with distilled water for injection to make up to the total of 4 ml), respectively, to perform inspection for their solubilities as well as to conduct investigation into appearance and contents immediately after dissolution and after storage at 25°C for 24 hours. The results are shown in Table 5. The lyophilized power showed excellent solubilities in all of these solvents, and was able to be dissolved quickly. In addition to this, the resulting solutions were observed to produce slight changes in appearance immediately after dissolution and after storage for 24 hours, but the changes were found to be so slight that they in no way influence the injectable solution. The solutions were found to show no change in the stage of solution while being observed to decrease slightly in content of compound (1). These solutions can be used as injectable solutions.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE Use of a compound of the formula wherein R¹ stands for hydrogen, methoxy or trifluoromethyl; R² and R³, being the same or different from each other, stand for hydrogen or methyl; and R⁴ stands for a straight or branched chain C₁₋₆ alkyl, C₂₋₆ alkenyl or C₂₋₆ alkynyl group which may optionally be substituted and n denotes 0 or 1; with the proviso that if R², R³ and R⁴ are methyl and n denotes 1, R¹ is not 5-methoxy; or a pharmacologically acceptable salt thereof, for the manufacture of a medicament for preventing or treating infectious diseases caused by the microorganism belonging to Campylobacter pylori. Use of a compound according to claim 1, wherein R¹ is hydrogen. Use of a compound according to claim 1, wherein R³ is hydrogen. Use of a compound according to any of claims 1 to 3, wherein R⁴ is a fluorinated alkyl group. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl}methylthiobenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,3-pentafluoropropoxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,3-pentafluoropropoxy)pyrid-2-yl}methylthiobenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3-tetrafluoropropoxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3-tetrafluoropropoxy)pyrid-2-yl}methylthiobenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,4,4-hexafluorobutyloxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,4,4-hexafluorobutyloxy)pyrid-2-yl}methylthiobenzimidazole. Claims for the following Contracting State : GR Use of a compound of the formula wherein R¹ stands for hydrogen, methoxy or trifluoromethyl; R² and R³, being the same or different from each other, stand for hydrogen or methyl; and R⁴ stands for a straight or branched chain C₁₋₆ alkyl, C₂₋₆ alkenyl or C₂₋₆ alkynyl group which may optionally be substituted and n denotes 0 or 1; or a pharmacologically acceptable salt thereof, for the manufacture of a medicament for preventing or treating infectious diseases caused by the microorganism belonging to Campylobacter pylori. Use of a compound according to claim 1, wherein R¹ is hydrogen. Use of a compound according to claim 1, wherein R³ is hydrogen. Use of a compound according to any of claims 1 to 3, wherein R⁴ is a fluorinated alkyl group. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl}methylthiobenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,3-pentafluoropropoxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,3-pentafluoropropoxy)pyrid-2-yl}methylthiobenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3-tetrafluoropropoxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3-tetrafluoropropoxy)pyrid-2-yl}methylthiobenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,4,4-hexafluorobutyloxy)pyrid-2-yl}methylsulfinylbenzimidazole. Use of a compound according to claim 1, wherein the compound is 2-{3-methyl-4-(2,2,3,3,4,4-hexafluorobutyloxy)pyrid-2-yl}methylthiobenzimidazole.

Inventors: IWAHI TOMOYUKI, SATOH HIROSHI, IWAHI, TOMOYUKI, SATOH, HIROSHI
Applicants: TAKEDA CHEMICAL INDUSTRIES LTD, TAKEDA CHEMICAL INDUSTRIES, LTD.
Application year: 1990
Main classification: A61K31
IPC codes: A61K31